Physician profile
Yaser Al-Solaiman
NPI 1922271089
$4,294.70
in general payments reported to CMS, 2019-2025
26 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,479 · 2020: $527 · 2021: $190 · 2022: $656 · 2023: $331 · 2024: $807 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $813.29 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $794.42 | 2019-2024 | Veltassa, Korsuva |
| Amgen INC. | $471.30 | 2019-2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $350.64 | 2019-2022 | |
| Eisai INC. | $311.06 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $271.99 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $148.51 | 2019-2023 | Farxiga |
| Abbott Laboratories | $139.15 | 2024 | Cardiomems |
| Horizon Therapeutics Plc | $126.92 | 2019-2023 | Krystexxa, Procysbi |
| Lilly USA, LLC | $119.70 | 2024 | Mounjaro |
| Genzyme Corporation | $119.70 | 2024 | |
| Travere Therapeutics, INC. | $101.69 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $96.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $65.48 | 2023 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $61.71 | 2024-2025 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $58.42 | 2019-2023 | Rayaldee |
| Akebia Therapeutics INC | $46.11 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $44.05 | 2019 | |
| Daiichi Sankyo INC. | $30.16 | 2019 | |
| Aurinia Pharma U.S., INC. | $27.90 | 2025 | Lupkynis |
| Shire North American Group INC | $23.14 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.22 | 2023 | |
| Novo Nordisk INC | $15.22 | 2025 | Ozempic, Rybelsus |
| Leadiant Biosciences, INC. | $13.34 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaser Al-Solaiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.